Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Loipa Medel Pérez"'
Autor:
Jenysbel de la C. Hernandez Reyes, Orestes Santos Morales, Laura Hernandez Moreno, Pedro Pablo Pino Alfonso, Elia Neninger Vinageras, Julia Lilliam Knigths Montalvo, Aliuska Aguilar Sosa, Amnely Gonzalez Morera, Patricia Lorenzo-Luaces Alvárez, Yadira Aguilar Venegas, Mayelin Troche Concepción, Loipa Medel Pérez, Yanela Santiesteban González, Lázara García Fernández, Lorena Regueiro Rodríguez, Amparo Macías Abrahan, Mayrel Labrada Mon, Kalet León Monzón, Danay Saavedra Hernández, Tania Crombet Ramos
Publikováno v:
Vaccines, Vol 12, Iss 8, p 833 (2024)
Background: EGFR has been suggested to contribute to COPD development and progression. Excessive ligand activation of the receptor leads to epithelial hyperproliferation and increased production of mucus, together with alterations in the primary cili
Externí odkaz:
https://doaj.org/article/f54899132f964f37ba644a2e570bf213
Autor:
Henrry Diaz Londres, Jorge Jiménez Armada, Aray Hernández Martínez, Anselmo A Abdo Cuza, Yamilka Hernández Sánchez, Aylin Granado Rodríguez, Sarahy Sepúlveda Figueroa, Egda M Llanez Gregorich, Mery L Torres Lahera, Francisco Gómez Peire, Teresita Montero González, Yaneth Zamora González, Ana L Añé Kouri, Addys González Palomo, Mayelin Troche Concepción, Loipa Medel Pérez, Patricia Lorenzo Luaces-Alvarez, Daymys Estévez Iglesias, Danay Saavedra Hernández, Mayra Ramos Suzarte, Tania Crombet Ramos
Publikováno v:
Immunotherapy. 14:521-530
Background: Lung injury and STAT1 deficit induce EGFR overexpression in SARS-CoV-2 infection. Patients & methods: A phase I/II trial was done to evaluate the safety and preliminary effect of nimotuzumab, an anti-EGFR antibody, in COVID-19 patients. P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbaacc7da1ccf6e6bcedb1b9b2fa625e
https://doi.org/10.2217/imt-2022-0027
https://doi.org/10.2217/imt-2022-0027